WST (West Pharmaceutical Services) Growth Rank: 9 (As of Jul. 30, 2026) — 10% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WST West Pharmaceutical Services Inc WST
95 GF Score
Price $339.59
GF Value $356.12
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Growth Rank?

West Pharmaceutical Services WST +0.63% 95 Growth Rank is 9 as of Jul. 30, 2026, which is 10% below its 10-year median of 10.00. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $356.12 (Fairly Valued). The stock has 8 warning signs investors should review.

West Pharmaceutical Services has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

West Pharmaceutical Services Growth Rank Related Terms

WST vs RMD, COO, SOLV: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Growth Rank distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Growth Rank falls into.


WST
95GF Score
West Pharmaceutical Services Inc WST
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
West Pharmaceutical Services (WST) has a Growth Rank of 9 as of Jul. 30, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on West Pharmaceutical Services and its competitors. This is 10% below median its historical median of 10.00. Over the past decade, West Pharmaceutical Services' Growth Rank has ranged from 5.00 to 10.00.
Is West Pharmaceutical Services' Growth Rank too high?
West Pharmaceutical Services' current Growth Rank of 9 is 10% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Growth Rank compare to RMD and COO?
West Pharmaceutical Services' Growth Rank of 9 can be compared against companies in the Medical Devices & Instruments industry. Historically, West Pharmaceutical Services' own Growth Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Growth Rank is 9, which is 10% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $356.12, compared to a current price of $339.59 — trading 4.6% below its estimated fair value. The current Growth Rank is 9, which is 10% below median its 10-year median of 10.00. West Pharmaceutical Services' overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Growth Rank is 9 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of $339.59 is trading 4.6% below its estimated GF Value™ of $356.12. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for WST:

  • Growth Rank: 9 (10% below median its 10-year median of 10.00)
  • GF Value™: $356.12 vs. price of $339.59 (4.6% below fair value)
  • GF Score™: 95/100 with 8 warning signs

No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for WST

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$339.59
Price
$356.12
GF Value